Pulmonx Co. (NASDAQ:LUNG) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $14.67.

Several research analysts have recently commented on LUNG shares. Canaccord Genuity Group boosted their target price on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Stifel Nicolaus decreased their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Finally, Wells Fargo & Company cut their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st.

Pulmonx Stock Performance

Shares of LUNG stock opened at $7.12 on Tuesday. The stock’s fifty day simple moving average is $7.23 and its 200 day simple moving average is $7.24. Pulmonx has a one year low of $5.46 and a one year high of $14.84. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 51.92%. During the same quarter in the prior year, the firm earned ($0.39) EPS. On average, equities analysts anticipate that Pulmonx will post -1.53 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In related news, Director Glendon E. French III sold 20,000 shares of the company’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the completion of the sale, the director now owns 1,091,974 shares in the company, valued at approximately $7,119,670.48. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, General Counsel David Aaron Lehman sold 5,765 shares of Pulmonx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total transaction of $38,567.85. Following the transaction, the general counsel now directly owns 203,348 shares of the company’s stock, valued at $1,360,398.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $6.52, for a total transaction of $130,400.00. Following the completion of the transaction, the director now directly owns 1,091,974 shares of the company’s stock, valued at $7,119,670.48. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,351 shares of company stock worth $361,494 in the last three months. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LUNG. nVerses Capital LLC bought a new position in shares of Pulmonx during the 3rd quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Pulmonx in the second quarter valued at approximately $37,000. Allspring Global Investments Holdings LLC increased its position in shares of Pulmonx by 609.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after acquiring an additional 7,316 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Pulmonx during the second quarter worth $93,000. Finally, EntryPoint Capital LLC bought a new stake in Pulmonx in the 1st quarter valued at $102,000. 91.04% of the stock is owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.